No Data
No Data
No Data
Craig-Hallum Sticks to Its Buy Rating for Harrow Health (HROW)
Harrow's Unit Wins Trademark Infringement Case Against OSRX
Express News | Harrow’s Imprimisrx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in Imprimisrx, LLC V. Osrx, Inc.
Former Harrow Unit Melt Announces Results for MELT-300 to Sedate for Surgery
Express News | Harrow Inc - Melt-300 Shows Statistical Superiority Over Midazolam and Placebo
Express News | Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Melt-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
loading...
loading...
No Data
No Data